Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Tyler S. Beyett"'
Autor:
Zhengnian Li, Jie Jiang, Scott B. Ficarro, Tyler S. Beyett, Ciric To, Isidoro Tavares, Yingde Zhu, Jiaqi Li, Michael J. Eck, Pasi A. Jänne, Jarrod A. Marto, Tinghu Zhang, Jianwei Che, Nathanael S. Gray
Publikováno v:
ACS Central Science, Vol 10, Iss 6, Pp 1156-1166 (2024)
Externí odkaz:
https://doaj.org/article/d5c6dbf338584d8bbd4b0121b594a89f
Autor:
Florian Wittlinger, Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner, Brandon T. Oligny, Surbhi P. Chitnis, Tyler S. Beyett, Alexander Rasch, Brian Buckley, Daniel A. Urul, Tatiana Shaurova, Earl W. May, Erik M. Schaefer, Michael J. Eck, Pamela A. Hershberger, Antti Poso, Stefan A. Laufer, David E. Heppner
Publikováno v:
Communications Chemistry, Vol 7, Iss 1, Pp 1-14 (2024)
Abstract Bivalent molecules consisting of groups connected through bridging linkers often exhibit strong target binding and unique biological effects. However, developing bivalent inhibitors with the desired activity is challenging due to the dual mo
Externí odkaz:
https://doaj.org/article/4d98b317db4743c79540cdb1697614f4
Autor:
Tyler S. Beyett, Ciric To, David E. Heppner, Jaimin K. Rana, Anna M. Schmoker, Jaebong Jang, Dries J. H. De Clercq, Gabriel Gomez, David A. Scott, Nathanael S. Gray, Pasi A. Jänne, Michael J. Eck
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Acquired drug resistance is common during chemotherapy. Here, the authors describe the structural basis and molecular mechanism by which allosteric and clinically approved, ATP-competitive inhibitors of EGFR synergize to overcome resistance in lung c
Externí odkaz:
https://doaj.org/article/b71e888015d54f3e90272f29edf5c334
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
Autor:
Ikuko Takeda Nakamura, Shinji Kohsaka, Masachika Ikegami, Hiroshi Ikeuchi, Toshihide Ueno, Kunhua Li, Tyler S. Beyett, Takafumi Koyama, Toshio Shimizu, Noboru Yamamoto, Fumiyuki Takahashi, Kazuhisa Takahashi, Michael J. Eck, Hiroyuki Mano
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-14 (2021)
Abstract Various genetic alterations of the fibroblast growth factor receptor (FGFR) family have been detected across a wide range of cancers. However, inhibition of FGFR signaling by kinase inhibitors demonstrated limited clinical effectiveness. Her
Externí odkaz:
https://doaj.org/article/1eb0d4f54965435d896fb494c2235251
Autor:
Jessica J. Waninger, Tyler S. Beyett, Varun V. Gadkari, Ronald F. Siebenaler, Carson Kenum, Sunita Shankar, Brandon T. Ruotolo, Arul M. Chinnaiyan, John J.G. Tesmer
Publikováno v:
Biochemistry and Biophysics Reports, Vol 29, Iss , Pp 101191- (2022)
Oncogenic mutations in KRAS result in a constitutively active, GTP-bound form that in turn activates many proliferative pathways. However, because of its compact and simple architecture, directly targeting KRAS with small molecule drugs has been chal
Externí odkaz:
https://doaj.org/article/5afdc55c4e9a499fb8675d06a6b666e1
Autor:
Pasi A. Jänne, Nathanael S. Gray, Michael J. Eck, Michael D. Cameron, Prafulla C. Gokhale, Man Xu, Stephen Wang, Michael J. Poitras, Pinar Ö. Eser, Nicholas P. Kwiatkowski, John M. Hatcher, Mika Lin, Alyssa Verano, Heidi M. Haikala, Yoonji Eum, Tyler S. Beyett, Jaebong Jang, Jieun Son
Supplementary Data from A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa51d44206e743a06a491f4c4226891
https://doi.org/10.1158/0008-5472.22431270
https://doi.org/10.1158/0008-5472.22431270
Autor:
Pasi A. Jänne, Nathanael S. Gray, Michael J. Eck, Michael D. Cameron, Prafulla C. Gokhale, Man Xu, Stephen Wang, Michael J. Poitras, Pinar Ö. Eser, Nicholas P. Kwiatkowski, John M. Hatcher, Mika Lin, Alyssa Verano, Heidi M. Haikala, Yoonji Eum, Tyler S. Beyett, Jaebong Jang, Jieun Son
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97a8ef884fce9cee6f7c5310978d793e
https://doi.org/10.1158/0008-5472.c.6513855.v1
https://doi.org/10.1158/0008-5472.c.6513855.v1
Autor:
Jieun Son, Jaebong Jang, Tyler S. Beyett, Yoonji Eum, Heidi M. Haikala, Alyssa Verano, Mika Lin, John M. Hatcher, Nicholas P. Kwiatkowski, Pinar Ö. Eser, Michael J. Poitras, Stephen Wang, Man Xu, Prafulla C. Gokhale, Michael D. Cameron, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne
Publikováno v:
Cancer Research. 82:1633-1645
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd25edc86a54a2b4204011c49a45ac0
https://doi.org/10.1158/0008-5472.can-21-2693
https://doi.org/10.1158/0008-5472.can-21-2693
Autor:
Tahereh Damghani, Florian Wittlinger, Tyler S. Beyett, Michael J. Eck, Stefan A. Laufer, David E. Heppner
Specificity for a desired enzyme target is an essential property of small-molecule inhibitors. Molecules targeting oncogenic driver mutations in the epidermal growth factor receptor (EGFR) kinase domain have had a considerable clinical impact due to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c7feb37a60ecf9afeb270384b957fee
https://doi.org/10.26434/chemrxiv-2023-v522v
https://doi.org/10.26434/chemrxiv-2023-v522v
Autor:
Florian Wittlinger, Blessing C. Ogboo, Calvin D. Pham, Ilse K. Schaeffner, Surbhi P. Chitnis, Tahereh Damghani, Tyler S. Beyett, Alexander Rasch, Brian Buckley, Daniel A. Urul, Tatiana Shaurova, Earl W. May, Erik M. Schaefer, Michael J. Eck, Pamela A. Hershberger, Stefan A. Laufer, David E. Heppner
The optimization of linkers that connect fragments within drug binding sites represents an impediment in fragment-based drug discovery (FBDD). To improve our understand of the molecular factors that enable effective fragment linking, we have produced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f963dd0ecbce0aeb30216c4895f60e0
https://doi.org/10.26434/chemrxiv-2023-cs3xn
https://doi.org/10.26434/chemrxiv-2023-cs3xn